On August 2 2023, EYEPOINT PHARMACEUTICALS ($NASDAQ:EYPT) released its financial results for the quarter ending June 30 2023, which marked a significant decrease in revenue and net income when compared to the same period in the previous year. The total revenue for the quarter was USD 9.1 million, down 21.3%, while the net income was USD -22.9 million, a decrease from -19.4 million in the same quarter of the prior year.
On Wednesday, EYEPOINT PHARMACEUTICALS reported their Q2 2023 earnings results for the fiscal year 2023. The stock opened the day at $11.8 and closed at $12.8, an increase of 0.7% from its previous closing price of 12.7. The company had a good quarter as their revenues and profits were higher than expected. This was mainly attributed to strong sales of its product portfolio, which includes products for ophthalmology and specialty pharmaceuticals.
This indicates that the company is well-positioned financially to take advantage of growth opportunities in the future. Overall, the Q2 earnings results for EYEPOINT PHARMACEUTICALS was positive and the stock has reacted accordingly by increasing its price. Investors have been optimistic about the company’s future prospects and their stock values have been increasing steadily over the past few months. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Eyepoint Pharmaceuticals. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Eyepoint Pharmaceuticals. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Eyepoint Pharmaceuticals. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Eyepoint Pharmaceuticals are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
At GoodWhale, we thoroughly analyze the fundamentals of EYEPOINT PHARMACEUTICALS to provide our clients with a comprehensive assessment. After looking at the Star Chart for EYEPOINT PHARMACEUTICALS, we can see that the company is strong in terms of asset growth, but weaker in terms of dividend and profitability. Furthermore, its Health Score of 4/10 indicates that it has an intermediate health score. This score takes into account the cashflows and debt of the company and suggests that it is likely to sustain future operations in times of crisis. After looking over the details of EYEPOINT PHARMACEUTICALS, we have concluded that the company falls into the ‘cheetah’ classification, meaning that it has achieved high revenue or earnings growth but is considered less stable due to lower profitability. This type of company may be of interest to certain types of investors who are looking for potential growth opportunities but need to be aware of the lower stability associated with such ventures. More…
Risk Rating Analysis
Star Chart Analysis
The company has a portfolio of products that are in various stages of development, including a treatment for age-related macular degeneration. The company’s competitors include NRX Pharmaceuticals Inc, Champions Oncology Inc, and MyMD Pharmaceuticals Inc.
– NRX Pharmaceuticals Inc ($NASDAQ:NRXP)
NXRX Pharmaceuticals Inc is a biopharmaceutical company that focuses on the development and commercialization of small molecule therapeutics to treat serious diseases. The company has a market capitalization of $54.79 million and a return on equity of -192.57%. NXRX Pharmaceuticals Inc is headquartered in Massachusetts, United States.
– Champions Oncology Inc ($NASDAQ:CSBR)
The company’s market cap is 95.74M as of 2022 and its ROE is 3.44%. The company’s main business is providing cancer research and treatment services.
– MyMD Pharmaceuticals Inc ($NASDAQ:MYMD)
MyMD Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing therapeutics for the treatment of cancer and other diseases. The company’s product pipeline includes MD-7246, MD-6640, and MD-0028. MyMD Pharmaceuticals was founded by John C. Long and James R. McCarter on May 11, 2010 and is headquartered in Vancouver, Canada.
Investors who are considering investing in EYEPOINT PHARMACEUTICALS should be aware of the company’s poor performance in the second quarter of its fiscal year 2023. Total revenue for the quarter was USD 9.1 million, a decrease of 21.3% compared to the same period in the previous year. The company also reported a net income of USD -22.9 million, a further decrease from -19.4 million in the same quarter last year. This paints a concerning picture for investors, and further analysis is required to determine whether or not EYEPOINT PHARMACEUTICALS is an attractive investment opportunity.